PDF factsheet
      Z

CEPT inhibition in cardiovascular prevention for all type of patients, clinical trials results

anacetrapib versus placebo
DEFINE, 2010
NCT00685776
anacetrapib 100mg fr 18 months
versus
placebo
patients with coronary heart disease or at high risk for coronary heart diseasedouble-blind
20 countries
REVEAL HPS-3 TIMI-55, 2017
NCT01252953
anacetrapib 100mg daily
versus
placebo
high risk patients already taking statinsdouble-blind
Follow-up duration: median 4 years
REALIZE, 2015
NCT01524289
oral anacetrapib 100 mg for 52 weeks
versus
placebo
patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular diseasedouble-blind
Follow-up duration: 52 weeks
dalcetrapib versus placebo
dal-VESSEL, 2011
dalcetrapib 600 mg daily
versus
placebo
men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dLdouble-blind
Follow-up duration: 12 weeks
dal-OUTCOMES, 2012
NCT00658515
dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event
versus
placebo
patients with recent acute coronary syndromedouble-blind
Follow-up duration: 31 montsh (median)
27 countries
evacetrapib versus placebo
ACCELERATE, 2017
NCT01687998
evacetrapib at adose of 130 mg
versus
placebo
Patients at a High-Risk for Vascular Outcomes who had at least one of the following conditions: an acutecoronary syndrome within the previous 30 to 365 days, cerebrovascular atheroscleroticdisease, peripheral vascular arterial disease, or diabetes mellitus with coronaryartery diseasedouble-blind
37 countries
torcetrapib versus placebo
RADIANCE 1, 2007
NCT00136981
atorvastatin combined with 60 mg of torcetrapib
versus
atorvastatin monotherapy
patients with heterozygous familial hypercholesterolemia open
Follow-up duration: 24 months
ILLUMINATE, 2007
NCT00134264
torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod)
versus
atorvastatin alone
patients at highcardiovascular riskdouble blind
Follow-up duration: 1.52y
7 countries
RADIANCE 2, 2007
torcetrapib 60mg daily (on top of atorvastatin attitrated dose)
versus
placebo +atorvastatin attitrated dose
patients with mixed dyslipidaemiadouble blind
Follow-up duration: 24 months
North America and Europe
ILLUSTRATE, 2007
NCT00134173
atorvastatin plus 60 mg of torcetrapib daily
versus
atorvastatin monotherapy
patients with coronary diseaseopen
Follow-up duration: 24 months
North America and Europe

  Options


in first

in second

  Filter